To improve the quality of life of patients with ankylosing spondylitis, research suggests that fatigue, poor sleep, and mental health need to be addressed in addition to managing disease activity and function.
US researchers have identified a number of chronic conditions associated with rheumatoid arthritis, including some that may predispose to RA development and others that may arise as a result of RA.
A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.
Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.
Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.
Follow-up results from the SPIRIT-H2H trial indicate that ixekizumab continues to improve joint and skin symptoms relative to adalimumab after 1 year of treatment among patients with psoriatic arthritis.
The small molecule phosphodiesterase 4 inhibitor apremilast reduces the number of oral ulcers and improves quality of life to a greater degree than placebo in people with Behçet’s syndrome, results of the phase III RELIEF study show.
The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.
Tofacitinib is effective for reducing the risk for disease flare in patients with polyarticular juvenile idiopathic arthritis, results of a randomized phase III study show.
The interleukin-17A inhibitor ixekizumab improves the signs and symptoms of nonradiographic axial spondyloarthritis relative to placebo, indicate findings from the phase III COAST-X trial.
A pooled analysis of data from the FINCH 1–3 studies has shown that 24 weeks of filgotinib treatment is well tolerated by a broad group of patients with rheumatoid arthritis, with an adverse event profile similar to that of its comparators.
Findings from the phase II/III SELECT-AXIS 1 trial suggest that treatment with upadacitinib may improve disease activity, function, and axial inflammation among biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to NSAIDs.
Patients with psoriatic arthritis who have achieved minimal disease activity on ixekizumab do better if they continue on the drug rather than stopping treatment, show findings from the SPIRIT-P3 study.
Methotrexate does not improve pain or physical function among people with symptomatic erosive hand osteoarthritis, indicate results from the placebo-controlled ADEM trial.
Trial findings reported at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, refute concerns that patients with rheumatic diseases taking TNF inhibitors should not be given the live varicella virus vaccine.
Naproxen and low-dose colchicine are similarly effective in the reduction of pain associated with gout flares, but patients receiving colchicine tend to experience more side-effects, show results from the multicenter, open-label CONTACT trial.
Certolizumab pegol significantly reduces the risk for acute anterior uveitis flare in patients with axial spondyloarthritis, show 48-week interim results from the C-VIEW trial.